Welcome to our dedicated page for Antiaging Quantu SEC filings (Ticker: AAQL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Antiaging Quantu's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Antiaging Quantu's regulatory disclosures and financial reporting.
Antiaging Quantum Living Inc. reported higher revenue but continued losses for the nine months ended December 31, 2025. Revenue rose to $1,021,894 from $529,714, mainly from technical operation support and maintenance services and initial activity at Anti-Aging Care LLC.
Gross profit increased to $763,117, but operating expenses of $1,224,781 led to a net loss of $467,138, narrower than the prior period’s $540,808. The company ended with a shareholders’ deficit of $300,616, cash of $936,910, and a working capital deficit of $113,526.
Management discloses substantial doubt about the ability to continue as a going concern, citing ongoing losses, an accumulated deficit of $1,876,850, and reliance on related-party funding, including $980,000 due to the president. During the period, $1,284,102 of promissory notes were converted into 4,280,340 Class A shares, reducing debt but increasing the share count to 34,275,340 as of February 13, 2026.
Antiaging Quantum Living Inc. is registering up to 4,280,340 shares of Class A Common Stock for resale by existing stockholders, representing shares issued upon automatic conversion of amended promissory notes at a fixed price of $0.30 per share. The company will not receive any proceeds from the sale of these shares, which may be sold from time to time in public or private transactions. Antiaging Quantum Living operates a small U.S. online advertising platform focused on New York professionals and has expanded into higher-growth PRC technical-service and non-medical health-management businesses under the “Dao Ling Doctor” brand, while facing significant risks related to limited operating history, need for additional capital, reliance on a single key executive, competition, thin OTC Pink trading, and potential dilution from future equity financing.
Antiaging Quantum Living Inc. has filed an S-1 to register up to 4,280,342 shares of its Class A Common Stock for resale by existing selling stockholders. These shares were issued upon automatic conversion of amended promissory notes at a fixed price of $0.30 per share, so no new shares are being created by this registration. The company will not receive any proceeds from the resale of these shares; any cash raised will go to the selling stockholders.
After the note conversions, the company reports 34,275,342 shares of Common Stock issued and outstanding, unchanged by the resale. Antiaging Quantum Living operates a small U.S. online advertising platform and higher-growth technical service and non-medical health-management businesses in China under its Dao Ling Doctor subsidiaries, but notes ongoing net losses, shareholder deficit, heavy reliance on a single key executive, the need for additional capital, penny-stock trading status on the OTC Pink under symbol AAQL, and significant competition and operational risks in both the U.S. and PRC markets.
Antiaging Quantum Living Inc. (AAQL) reported its quarterly results for the period ended September 30, 2025. Six-month revenue reached $681,602, up from $375,243 a year ago, driven by technical operation support and maintenance services. Gross profit was $559,205 with an 82.04% gross margin. The company recorded a six-month net loss of $194,970, improving from a loss of $411,654.
For the latest quarter, revenue was $390,164 and net loss was $61,598. Cash and cash equivalents were $455,446 as of September 30, 2025, with working capital of $23,279. Management disclosed substantial doubt about continuing as a going concern due to ongoing losses, limited working capital, and reliance on external funding.
Financing relied on related parties: amounts due to related parties were $860,000, and non‑interest‑bearing promissory notes and loans to related parties totaled $1,698,330. Customer concentration was elevated, with 100% of six‑month revenue and accounts receivable from a single customer. Class A shares outstanding were 29,995,000 as of November 12, 2025.